NAD Finds Salonpas Duration Claim Supported; Recommends Hisa

NAD Finds Salonpas Duration Claim Supported; Recommends Hisamitsu America Discontinue Comparative Pain Relief, Onset of Action, Range of Motion Claims


NAD Finds Salonpas Duration Claim Supported; Recommends Hisamitsu America Discontinue Comparative Pain Relief, Onset of Action, Range of Motion Claims
News provided by
Share this article
Share this article
NEW YORK, March 10, 2021 /PRNewswire/ -- The National Advertising Division (NAD) of BBB National Programs determined that Hisamitsu America, Inc. supported its duration claims that Salonpas Pain Relief Patch Large "works for up to 12 hours" and "provides relief for up to 12 hours." NAD also determined that Hisamitsu provided a reasonable basis for the challenged claims comparing the Salonpas patch's regulatory pathway to competitor products. However, NAD has recommended that Hisamitsu discontinue the following parity and product performance claims:

Related Keywords

, Hisamitsu America Inc , National Programs , National Advertising Division , Hisamitsu America , Salonpas Pain Relief Patch Large , Glaxosmithkline Consumer Healthcare , Voltaren Topical , New Drug , Salonpas Pain Relief Patch , New Drug Applications , Better Business Bureaus , Bbb National Programs , ஹிசாமிட்சு அமெரிக்கா இன்க் , தேசிய ப்ரோக்ர்யாம்ஸ் , ஹிசாமிட்சு அமெரிக்கா , கிளாக்சோஸ்மித்க்லைன் நுகர்வோர் சுகாதாரம் , புதியது மருந்து , புதியது மருந்து பயன்பாடுகள் , சிறந்தது வணிக பணியகங்கள் , பிபிபி தேசிய ப்ரோக்ர்யாம்ஸ் ,

© 2025 Vimarsana